Two Sigma Investments LP Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Two Sigma Investments LP bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 109,373 shares of the biopharmaceutical company's stock, valued at approximately $3,594,000. Two Sigma Investments LP owned 0.19% of Agios Pharmaceuticals as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in Agios Pharmaceuticals during the 4th quarter valued at about $49,290,000. Fisher Asset Management LLC grew its stake in Agios Pharmaceuticals by 12.3% during the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock valued at $31,567,000 after purchasing an additional 105,333 shares during the last quarter. Deutsche Bank AG grew its stake in Agios Pharmaceuticals by 39.7% during the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after purchasing an additional 265,637 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC grew its stake in Agios Pharmaceuticals by 3.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock valued at $30,146,000 after purchasing an additional 34,689 shares during the last quarter.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Price Performance

AGIO traded up $0.74 during trading on Tuesday, hitting $33.37. The company had a trading volume of 697,603 shares, compared to its average volume of 677,942. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The business has a 50-day moving average of $28.68 and a 200-day moving average of $34.80. The company has a market cap of $1.93 billion, a PE ratio of 2.94 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on AGIO shares. Scotiabank dropped their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.